|
May 11
|
Gritstone bio First Quarter 2024 Earnings: Misses Expectations
|
|
May 9
|
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
|
May 2
|
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
|
|
Apr 30
|
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
|
|
Apr 29
|
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
|
|
Apr 15
|
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
|
|
Apr 8
|
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
|
|
Apr 8
|
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
|
|
Apr 2
|
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
|
|
Apr 1
|
Gritstone bio Announces Proposed Public Offering
|
|
Apr 1
|
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite...
|
|
Mar 19
|
3 Speculative Stocks You Can Buy for $3 or Less
|
|
Mar 8
|
Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates
|
|
Mar 7
|
Gritstone bio Full Year 2023 Earnings: Beats Expectations
|
|
Mar 5
|
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
|
|
Jan 17
|
Gritstone bio to Participate in Upcoming Investor Conference
|
|
Sep 5
|
Gritstone bio to Participate in Upcoming Investor Conferences
|
|
Aug 9
|
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
|
|
Aug 7
|
Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
|
|
Jul 4
|
Gritstone bio (NASDAQ:GRTS) shareholders have endured a 70% loss from investing in the stock three years ago
|